In an era where most product- and innovation-hungry Big Pharma have been desperately promoting themselves as a ‘partner of choice,’ it’s perhaps easy to forget what can go wrong when a biotech entrusts an important asset to a larger partner.
Except if you’re Basilea Pharmaceutica Ltd.. So frustrated had this biotech become with the efforts—or the perceived lack thereof—of...


